Case Report: Dupilumab therapy for immune checkpoint inhibitor-induced bullous pemphigoid enables dual immunotherapy initiation in progressive malignant melanoma
{{output}}
Immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1 and CTLA-4 have transformed the treatment of malignant melanoma, significantly improving patient survival rates. However, these therapies often result in immune-related adverse events, with cutaneous to... ...
